PONENTE

  • What's involved: PONENTE: A Multicenter, Open-label, Phase 3b Efficacy and Safety Study of Benralizumab 30mg Administered Subcutaneously to Reduce Oral Corticosteroid Use in Adult Patients with Severe EosinophilicAsthma on High Dose Inhaled Corticosteroid plus Long-acting β2 Agonist and Chronic Oral Corticosteroid Therapy
  • Take part: Open
  • Principal Investigator: Professor Tim Harrison
Research Theme | Respiratory | Open Trials

What's involved

PONENTE: A Multicenter, Open-label, Phase 3b Efficacy and Safety Study of Benralizumab 30mg Administered Subcutaneously to Reduce Oral Corticosteroid Use in Adult Patients with Severe EosinophilicAsthma on High Dose Inhaled Corticosteroid plus Long-acting β2 Agonist and Chronic Oral Corticosteroid Therapy

Principal Investigator

Professor Tim Harrison

Take part

Open
Back to all trials

Contact Us

NIHR Biomedical Research Centre: Nottingham
Research & Innovation
D Floor (via South Block)
Nottingham University Hospitals NHS Trust
Queen’s Medical Centre
Derby Road
Nottingham
NG7 2UH

Telephone: 0115 924 9924

Director: Professor Ian Hall

Hosted by

Nottingham University Hospitals Logo

Nottingham University Hospitals Logo

We are a partnership between Nottingham University Hospitals NHS Trust and the University of Nottingham, supported by NHS and academic partners in Nottingham and across the East Midlands.

Website by Volute